GI Innovation said Tuesday it has signed a memorandum of understanding with Korea’s AimedBio to co-develop a treatment for glioblastoma, the most aggressive and common form of brain cancer.

The companies plan to pursue accelerated approval for a combination therapy using GI‑102, GI Innovation’s immunotherapy candidate, in patients with recurrent glioblastoma who have received prior radiation. GI‑102 has shown antitumor activity in preclinical models.

AimedBio will lead clinical development. Revenue from commercialization will be split under a pre-agreed ratio.

“This agreement is aimed at securing conditional approval and early commercialization through a phase 2 trial,” said GI Innovation CEO Jang Myoung-ho.